AMG 211 (Amgen)

AMG 211 (also known as MEDI-565) is a bispecific T-cell engager (BiTE) of approximately 55 kDa, designed to target the carcinoembryonic antigen (CEA, CD66e) on tumor cells and the CD3 epsilon subunit on T-cells. Developed by Amgen and MedImmune, it functions by cross-linking T-cells with CEA-expressing cancer cells, leading to T-cell activation and the directed lysis of the tumor cells. In clinical research conducted at the University Medical Center Groningen, AMG 211 was radiolabeled with Zirconium-89 (89Zr-AMG211) for use in PET imaging to non-invasively quantify drug distribution and tumor uptake in patients with relapsed or refractory gastrointestinal adenocarcinoma. This imaging approach aims to identify patients most likely to benefit from BiTE therapy by evaluating target expression heterogeneity and the impact of continuous intravenous exposure on tumor uptake.

Other names

89Zr-AMG21189Zr-MEDI-565Zirconium-89 AMG 211Zirconium89 AMG 211Zirconium 89 AMG 211anti-CEA/CD3 BiTE